ERBB2 and breast carcinoma: Trastuzumab emtansine (T-DM1) should be considered as a second-line treatment option for patients with HER2-positive breast cancer who have progressed after prior treatment with a taxane and trastuzumab, in settings where T-DXd is contraindicated (expert recommendation).